In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration ...

It’s been 13 years since the FDA approved its first therapeutic vaccine – Dendreon Pharma’s Provenge (sipuleucel-T) for prostate cancer, which was not a commercial success – and since then ...

Objective: To review the activity of 3 new agents approved for the management of advanced castration-resistant prostate cancer (CRPC): sipuleucel-T, cabazitaxel, and abiraterone acetate.

One therapeutic cancer vaccine that has remained in development is sipuleucel-T (Provenge; Dendreon) (Table 1), which was widely expected to receive approval in 2007 following a positive vote from ...

We have our slowly progressing cancers where we might leverage, you know, something like metastasis-directed radiation for oligoprogression or Sipuleucel-T. And then we have really aggressive ...